Keiko Minashi

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Yoon‐Koo Kang, Narikazu Boku, Taroh Satoh et al. · The Lancet · 2017 · 2.2K citations · Full text

Esophageal Cancer, Gastrointestinal Oncology, Least Two +8

Early Detection of Superficial Squamous Cell Carcinoma in the Head and Neck Region and Esophagus by Narrow Band Imaging: A Multicenter Randomized Controlled Trial

Manabu Muto, Keiko Minashi, Tomonori Yano et al. · Journal of Clinical Oncology · 2010 · 679 citations · Full text

Development and evaluation of FSSG: frequency scale for the symptoms of GERD

Motoyasu Kusano, Yasuyuki Shimoyama, Sayaka Sugimoto et al. · Journal of Gastroenterology · 2004 · 473 citations

Frequency Scale, Gastroenterology, Diagnosis +2

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

Toshihiro Kudo, Yasuo Hamamoto, Ken Kato et al. · The Lancet Oncology · 2017 · 378 citations

Surgical Oncology, Esophageal Cancer, Nivolumab Treatment +8

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1

Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa et al. · Esophagus · 2023 · 345 citations · Full text

Epidemiology, Part 1, Esophagus +14